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incidences were large. These results support birth cohort 
eﬀ ects and higher rates of sexual infection in women 
postulated by prevalence studies.5,6 They also suggest 
that HTLV-1 incidence will continue to fall in Japan as 
the higher risk cohorts age and die. 
Only a few other studies have attempted to determine 
the incidence of HTLV-1 and even fewer have used 
representative samples of general populations. Two 
studies in the USA and one in Brazil estimated incidence 
in repetitive blood donors and found results that are 
probably lower than, but of similar magnitude as, 
general population rates. Glynn and colleagues7 and Zou 
and colleagues8 in the USA reported incidence rates of 
1·6 new infections per 100 000 person-years and 0·21 new 
infections per 100 000 person-years, respectively. The 
diﬀ erence between them is probably due to diﬀ ering 
geographic areas served by the sampled blood centres. In 
Brazil, Carneiro-Proietti and colleagues9 reported a rate 
of 3·6 per 100 000 person-years, quite similar to Satake’s 
estimate for Japan and about three times higher than in 
the USA, consistent with known HTLV-1 epidemiology. 
Three other studies found much higher incidence, 
probably because they studied higher-risk populations, 
including a hyperendemic island in Okinawa, Japan (1·0 per 
1000 person-years),10 a sexually transmitted infection clinic 
in Jamaica (9·0 per 1000 person-years),11 and a community 
sample with high HIV prevalence in Guinea-Bissau (1·7 per 
1000 person-years).12
Two main conclusions can be drawn. First, incidence 
data for HTLV-1 are scarce in many countries and 
therefore insuﬃ  cient to responsibly inform and assess 
prevention eﬀ orts by public health agencies and allow 
for international comparisons. Second, since large 
population-based incidence studies are unlikely to be 
done for HTLV-1, studies that include repeat blood donors 
are a practical and reasonable alternative for international 
comparisons and monitoring secular trends.
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Tuberculosis: a private and public health and data mix
The clue in the title lies in the phrase public health. Data 
for understanding the health status of communities and 
nations comprise a fundamental public good.1 Public 
health data can only be captured and curated eﬀ ectively 
if suﬃ  cient resources and determination are deployed 
for the purpose. But, from private sector perspectives of 
proﬁ ts and shareholders, it might seem entirely reasonable 
not to prioritise the collection of public health data.
In The Lancet Infectious Diseases, Nimalan Arinaminpathy 
and colleagues2 tackle a speciﬁ c manifestation of this 
public–private dichotomy in examining the complex 
mix of tuberculosis treatment uptake in India. India 
is a country where health services are undergoing a 
rapid transition from the former domination of the 
government sector into a public–private plurality. In a 
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inequities, this plurality of health services is likely to persist 
for a long time. Managing infectious diseases associated 
with poverty, like tuberculosis, would traditionally have 
been regarded as a governmental responsibility. The new 
ﬁ ndings suggest that about two-thirds of tuberculosis 
treatment in India is now being delivered by the private 
sector. How can that important private sector input best 
be monitored?
The USA, with arguably the world’s largest private-
dominated health-care system, provides an interesting 
comparison. The Centers for Disease Control and 
Prevention, as the national health protection agency, 
carries responsibility for documenting tuberculosis 
(which has long been a nationally notiﬁ able disease), in 
the form of an annual report.3 Nevertheless, as in India, 
delivery of tuberculosis treatment is a public–private mix, 
with a quarter of clinical care for tuberculosis delivered 
through the private sector.4 One has to assume in the 
USA that the procedures required of the private sector for 
notifying tuberculosis cases to the public authorities are 
suﬃ  ciently robust and well-enforced.
India only made tuberculosis a notiﬁ able disease 
in 2012, following reports of multiple drug-resistant 
disease.5 To what extent mandatory reporting has 
facilitated the extraction of reliable data from the private 
sector is uncertain, particularly given that half of private 
practitioners in a survey cited lack of time as a reason 
for failing to notify tuberculosis cases in Chennai.6 The 
compliance of the Indian private health sector in terms of 
notifying tuberculosis (and possibly other diseases) thus 
seems to be a major obstacle to gathering public health 
data. Alternative and less direct approaches are therefore 
important for reaching any realistic national picture 
of tuberculosis treatment in India, where a substantial 
proportion of worldwide cases occur.7 But are such 
indirect methods appropriate and relevant?
Arinaminpathy and colleagues2 chose to move their 
focus upstream from data at the patient-provider level 
to drug supply statistics. Since there is no single drug 
uniquely and solely indicated for treating tuberculosis, 
this approach involved some fairly brave assumptions. 
Sales of drugs containing rifampicin were chosen as the 
key indicator on the basis of having fewer indications 
than other drugs for non-tuberculosis treatment. 
Patient-months of treatment had to be measured, 
since there were no direct data on individual treatment 
duration. The contribution of false-positive diagnoses 
of tuberculosis had to be considered. Putting everything 
into the pot, the public health burden of tuberculosis 
in India appears to be even higher than has often been 
assumed, thus representing a major challenge to both 
the public and private health sectors. The approach 
taken here seems to be useful, but is by no means 
equivalent to having the individual-level data one would 
wish for.
In an era of global concern about tuberculosis, 
including HIV co-infection and multiple drug-resistant 
organisms, complacency about gathering tuberculosis 
treatment data and establishing the corresponding 
magnitude of public health burdens is not acceptable. 
An increasing number of countries with high 
tuberculosis burdens are also encountering growth in 
their private health sectors. Private sector involvement 
might not be a bad thing in itself, but mechanisms to 
extract reliable public health data from private health 
providers on tuberculosis and other diseases of public 
health concern are essential. Just as public health 
systems implicitly capture data as one of their intrinsic 
functions, public resources must be more eﬀ ectively 
deployed for capturing and curating data of public 
interest from the private sector.
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